# reload+after+2024-01-20 09:43:15.849796
address1§245 First Street
address2§Suite 1400
city§Cambridge
state§MA
zip§02142
country§United States
phone§617 871 2098
fax§617 871 2099
website§https://www.akebia.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§204
companyOfficers§[{'maxAge': 1, 'name': 'Mr. John P. Butler MBA', 'age': 59, 'title': 'CEO, President & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 1287060, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michel  Dahan', 'age': 44, 'title': 'Senior VP & COO', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 734726, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Nicole R. Hadas J.D.', 'age': 50, 'title': 'Senior VP, Chief Legal Officer & Secretary', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 687379, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Steven Keith Burke', 'age': 62, 'title': 'Senior VP of Research & Development and Chief Medical Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 766574, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ellen E. Snow CPA, CGMA', 'age': 51, 'title': 'Senior VP, CFO, Treasurer & Principal Accounting Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Tracey  Vetterick', 'title': 'Vice President of Portfolio Strategy & Corporate Administration', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mercedes  Carrasco', 'title': 'Director of Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Douglas  Jermasek M.B.A.', 'age': 62, 'title': 'Vice President of Marketing & Strategy', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Meredith  Bowman', 'title': 'Senior Vice President of People', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kimberly  Garko', 'title': 'Senior Vice President of Quality, Manufacturing & Pharmaceutical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§6
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.795
priceToSalesTrailing12Months§1.4356478
currency§USD
dateShortInterest§1702598400
forwardEps§-0.29
exchange§NCM
quoteType§EQUITY
shortName§Akebia Therapeutics, Inc.
longName§Akebia Therapeutics, Inc.
firstTradeDateEpochUtc§1395322200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f0f4b70d-7a99-33e9-84f9-09ab2c0b6996
gmtOffSetMilliseconds§-18000000
targetHighPrice§5.0
targetLowPrice§4.0
targetMeanPrice§4.33
targetMedianPrice§4.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§0.867
grossMargins§0.38731
ebitdaMargins§0.08644
trailingPegRatio§None
